Genscript BiotechGNNSF 66 Market Cap is $3,663.8 Mil as of Jul. 04, 2026. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.48 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,426 Biotechnology companies, Genscript Biotech ranks better than 92.57% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Genscript Biotech's share price for the quarter that ended in Dec. 2025 was $1.665. Genscript Biotech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 2,184.7 Mil. Therefore, Genscript Biotech's market cap for the quarter that ended in Dec. 2025 was $3,637.5 Mil.
Genscript Biotech's quarterly market cap
increased
from Dec. 2024 ($2,722.8 Mil) to Jun. 2025 ($4,794.6 Mil) but then
declined
from Jun. 2025 ($4,794.6 Mil) to Dec. 2025 ($3,637.5 Mil).
Genscript Biotech's annual market cap
declined
from Dec. 2023 ($5,174.3 Mil) to Dec. 2024 ($2,722.8 Mil) but then
increased
from Dec. 2024 ($2,722.8 Mil) to Dec. 2025 ($3,637.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Genscript Biotech's Enterprise Value for Today is $3,116.0 Mil.
Genscript Biotech (OTCPK:GNNSF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Genscript Biotech Market Cap Related Terms
Genscript Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genscript Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Genscript Biotech's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a Market Cap of $3,663.8 Mil as of Jul. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Genscript Biotech and its competitors. According to the industry distribution chart, Genscript Biotech ranks #106 out of 1426 companies in the Biotechnology industry, placing it in the top 7.4%.
Is Genscript Biotech's Market Cap too high?
Genscript Biotech's current Market Cap is $3,663.8 Mil. The Biotechnology industry median Market Cap is 119.23. Genscript Biotech's value of $3,663.8 Mil is 2973% above this industry median. Based on the distribution chart, Genscript Biotech ranks #106 out of 1426 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #106 out of 1426 companies for Market Cap. This places Genscript Biotech in the top 7% of its industry — outperforming the majority of peers. The industry median Market Cap is 119.23. Genscript Biotech's value of $3,663.8 Mil is 2973% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current Market Cap of $3,663.8 Mil is 2973% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Market Cap is $3,663.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.48, compared to a current price of $1.60 — trading 35.5% below its estimated fair value. The current Market Cap is $3,663.8 Mil and 2973% above the Biotechnology industry median of 119.23. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Market Cap is $3,663.8 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.60 is trading 35.5% below its estimated GF Value™ of $2.48.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
Market Cap: $3,663.8 Mil
GF Value™: $2.48 vs. price of $1.60 (35.5% below fair value)
Industry Position: 2973% above the Biotechnology median (#106 of 1426)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
